Hi everyone,

Here is the quarterly portfolio update #1.

I have added some new companies to portfolio with some added insights.

There are two new added aspects of learning that I decided to add to the portfolio.

1. Mean Reversion

Added companies from beaten down sector such as Agro Chemicals with their margins reverting to long term average. I decided to buy companies on basis of their balance sheet as companies with less debt will be able to recover quickly than its peers. Added Sharda Cropchem and PI Industries with this theory in mind.

2. Basket Approach

In case of not being sure with which company to pick from any sector, buy multiple companies with small allocations to ride the tailwinds provided by sector. Added KNR Construction and PSP Projects from construction sector to allocate some investments in rising government spending in infrastructure sector.

• No sell transaction during the quarter.

• Increased holding in Infosys from previous post.

Rest of changes in allocation are based on market performance of the company.

Just wanted to say that I keep coming back to this thread every time I need some answers or want to check on the key monitorables, guidance etc. It almost always answers all my questions so thank you once again ! After building conviction in the fundamentals of the company, I was just tracking it from the sidelines for a few months to see what the support range was for this stock. I felt like 200-220 was that zone and when it recently took support there and moved up (4th attempt in the last 6-8 months), I finally bought it 3-4 weeks ago. Eager to see how the next set of results pan out.

Note – Invested, biased and not qualified or knowledgeable to give any kind of investment/trading advice.

“Successful Use of Investigational Antibiotic, Zaynich (Zidebactam/Cefepime- WCK 5222) to Treat a Cancer Patient in US with Chronic Bilateral Thigh Infection Caused by an Extreme-Drug
Resistant Pseudomonas”.

I also loved this one.

WCK 5222 has been used successfully for a US patient!

Cleared out a nasty infection of metallo-β-lactamase-harbouring P aeruginosa in a young cancer patient, who was administered the drug on compassionate grounds, since there were no other treatment options left. 4 weeks, all clear, and well tolerated.

Feel proud that an Indian company has innovated like this.

Disclosure: Invested from lower levels, this is one of my investments “from the heart” (though I know one should never do this, what’s the fun if you don’t listen to your heart?)